tickerreport.com
Positivewww.tickerreport.com ·
Equillium Nasdaqeq Lowered to Sell Rating by Wall Street Zen
HistoricEcon PriceInsidersAutoimmune Diseases
Topic context
This topic has been covered 357755 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEquillium is a biotech company with no approved products or revenue; the downgrade reflects weak earnings and insider selling. No direct commercial mechanism for broader sectors; impact is company-specific and limited to investor sentiment.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Equillium (EQ) downgraded to sell by Wall Street Zen on May 17, 2026.
- Stock opened at $2.18, market cap $137.84M, 52-week range $0.27-$2.70.
- Q1 2026 EPS of ($0.06) missed consensus estimate of ($0.04).
- Insiders sold significant shares; 17.84% insider ownership.
- Average analyst price target $7.67, consensus 'Moderate Buy'.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
timesofindia.indiatimes.com
Fuel Rates Hiked Petrol Price Increased From Rs 94 77 to Rs 97 77 Diesel From Rs 87 67 to Rs 90 67 Check New List of Rates
auto.economictimes.indiatimes.com